Earnings Insights · ABBV · Q3 FY2026
AbbVie Q3 2026 Earnings: Skyrizi and Rinvoq Drive Another Guidance Increase
By AlgovestIQ ResearchPublished
Read AbbVie’s results announcement (Form 8-K, filed Oct 30, 2026)
Key earnings findings
AbbVie (ABBV) Q3 FY2026 · results discussed on the earnings call · Form 8-K filed
- AbbVie reported Q3 FY2026 revenue of $17.40B against the $17.32B analyst estimate, a 0.5% beat, and EPS of $3.82 against the $3.73 analyst estimate, a 2.4% beat.
- Adjusted EPS more than doubled to $3.82, while management raised full-year revenue and adjusted EPS guidance again.
- ABBV closed at $294.89 on Oct 30, 2026, up 1.4% from $290.79 on Oct 29, 2026, the last close before the results were released.
Sources: AbbVie results announcement (SEC), the Q3 FY2026 earnings call, and AlgovestIQ reported-results and market data. All references
Did AbbVie beat earnings expectations?
- EPS has beaten the estimate in 7 of the most recent reported quarters.
- Revenue surprise across the last 8 reported quarters has ranged from 0.5% to 3.2%.
Reported figures against analyst estimates, compiled from AlgovestIQ data.
AbbVie reported third-quarter revenue of $17.404B, up 10.3% year over year, and GAAP diluted EPS of $2.37, compared with $0.10 a year earlier. Adjusted EPS more than doubled to $3.82, while management raised full-year revenue and adjusted EPS guidance again. The central investment story remains the durability of AbbVie’s post-Humira growth engine: Skyrizi and Rinvoq continued to expand rapidly, neuroscience remained a second major growth contributor, and the company added pipeline depth through the Apogee Therapeutics acquisition.
The quarter was not uniformly strong. Oncology grew less than 1% as Imbruvica declined 26.1%, while aesthetics revenue fell 1.8% operationally amid continued softness in dermal fillers. Earnings comparisons also benefit from a much lower acquired IPR&D charge than in the prior-year period.
Earnings Snapshot
| Metric | Reported | Change |
|---|---|---|
| Net revenue | $17.404B | +10.3% reported; +10.5% operational |
| GAAP diluted EPS | $2.37 | Over +100% |
| Adjusted diluted EPS | $3.82 | Over +100% |
| Immunology revenue | $9.165B | +16.3% |
| Neuroscience revenue | $3.389B | +19.4% |
| Oncology revenue | $1.696B | +0.8% |
| Aesthetics revenue | $1.176B | -1.4% |
| Skyrizi revenue | $5.776B | +22.7% |
| Rinvoq revenue | $2.706B | +23.9% |
| Humira revenue | $683M | -31.2% |
| GAAP operating margin | 36.0% | Not disclosed |
| Adjusted operating margin | 48.7% | Not disclosed |
| Free cash flow, first nine months | Approximately $14B | Not disclosed |
| Cash balance, September 30 | $10.8B | Not disclosed |
The Bigger Story
AbbVie’s growth is increasingly concentrated in newer immunology and neuroscience franchises rather than legacy Humira revenue. Skyrizi and Rinvoq generated a combined $8.482B in third-quarter sales, up more than 22% each, more than offsetting the continued biosimilar-driven decline in Humira.
The company also raised its full-year immunology outlook to $34.9B, including $21.8B for Skyrizi and $10.3B for Rinvoq. Those targets reinforce management’s view that both products can continue growing despite intensifying competition in inflammatory bowel disease, psoriasis and other immune-mediated diseases.
Beyond the current portfolio, AbbVie is trying to extend that franchise through acquisitions and combination therapies. The completed Apogee acquisition added late-stage and earlier-stage immunology assets, while AbbVie has started a Phase IIb program combining Skyrizi with complementary mechanisms in Crohn’s disease and ulcerative colitis. Those programs are strategically important because they could determine whether AbbVie can maintain immunology leadership as Skyrizi and Rinvoq mature.
Revenue and Operating Performance
Immunology remained AbbVie’s largest and most important growth driver. Portfolio revenue increased 16.3% to $9.165B, led by Skyrizi revenue of $5.776B and Rinvoq revenue of $2.706B.
Skyrizi grew 22.7%, supported by demand across psoriasis and inflammatory bowel disease. Management said Skyrizi continues to capture roughly half of new or switching psoriasis patients and about half of in-play starts in IBD relative to its principal competitor. The FDA approval of subcutaneous induction dosing for Crohn’s disease could strengthen that position, particularly as management believes the dosing option offers a more convenient alternative to intravenous induction.
Rinvoq grew 23.9%, with management highlighting momentum in rheumatoid arthritis and IBD. The company expects potential U.S. approvals in vitiligo and alopecia areata over the next several months. Management expects those two dermatology indications to contribute nearly $2B of peak sales, although those expectations remain dependent on regulatory approvals and commercial execution.
Humira revenue fell 31.2% to $683M as biosimilar competition continued. The decline remains a material offset to AbbVie’s newer immunology products, but its absolute contribution is now much smaller than Skyrizi and Rinvoq.
Neuroscience revenue increased 19.4% to $3.389B. Vraylar rose 14.3% to $1.068B, Botox Therapeutic increased 9.8% to $1.080B, and the oral migraine portfolio continued to expand. Ubrelvy revenue grew 26.9% to $449M, while Qulipta rose 38.2% to $398M.
Parkinson’s disease is becoming a more meaningful strategic area. Vyalev revenue reached $286M, and management said it remains on track to exceed $1B in revenue for the full year. AbbVie also recently launched Juvmo, its newly approved Parkinson’s therapy. Management expects the launch to build gradually because broader Medicare coverage is not expected until 2028.
Oncology revenue was essentially flat at $1.696B. Venclexta grew 10.7% to $803M, while Elahere increased 31.0% to $224M and Epkinly grew 57.7% to $108M. Those gains were largely offset by a 26.1% decline in Imbruvica revenue to $522M, reflecting IRA pricing and competitive pressure.
Aesthetics remained the weakest major business. Revenue fell 1.4% to $1.176B, with Juvederm revenue declining 11.9% to $222M. Botox Cosmetic grew 4.9% to $669M, but management said lower consumer confidence and economic uncertainty have continued to pressure the category. It sees early signs of stabilization, though that has not yet translated into broad portfolio growth.
Profitability and Margins
AbbVie reported GAAP diluted EPS of $2.37 and adjusted EPS of $3.82. Both figures included a $0.11-per-share unfavorable impact from acquired IPR&D and milestone expense.
The year-over-year EPS comparison requires caution. Third-quarter 2025 results included a $2.7B acquired IPR&D and milestone charge, equivalent to a $1.50-per-share impact, along with an $847M intangible impairment. In the latest quarter, acquired IPR&D and milestone expense was $216M. The reported increase in GAAP and adjusted EPS therefore reflects both operating growth and a substantially easier comparison for acquisition-related charges.
GAAP operating margin was 36.0%, while adjusted operating margin was 48.7%. The difference primarily reflects intangible amortization, acquisition and integration costs, and changes in the fair value of contingent consideration.
Adjusted gross margin was 85.1%, adjusted R&D expense was 13.9% of revenue, and adjusted SG&A was 21.2% of revenue. Adjusted net interest expense was $688M, while the adjusted tax rate was 13.6%.
The quarter’s adjusted EPS also excluded $0.79 per share of intangible asset amortization, $0.22 per share of acquisition and integration costs, and $0.46 per share related to a change in the fair value of contingent consideration. These adjustments are significant, making the GAAP-adjusted gap an ongoing consideration for investors assessing underlying earnings conversion.
Demand, Customers and Pricing
Management described sustained demand for Skyrizi and Rinvoq despite competition in dermatology and IBD. For Skyrizi, the company expects the newly approved subcutaneous Crohn’s induction regimen to improve its competitive position after payer access is established, which management expects to take roughly 60 days or somewhat longer.
Management also said its 2027 payer discussions are progressing broadly in line with prior years. It expects strong access for its portfolio and indicated that low-single-digit rebate concessions remain a reasonable assumption for immunology products.
In aesthetics, demand remains less predictable. Botox Cosmetic showed modest growth, but Juvederm and other aesthetics products remain exposed to softer consumer spending. The commercial rollout of Boey, AbbVie’s short-duration toxin, is underway in Europe and Canada. In the U.S., AbbVie expects to resubmit Boey to the FDA before year-end following a complete response letter related to manufacturing assessments, with a potential decision expected in mid-2027.
What is AbbVie’s guidance for full-year 2026 and Q4 2026?
AbbVie raised its full-year 2026 adjusted diluted EPS guidance to $13.95 to $13.99, from $13.76 to $13.96 previously. The revised range includes a $0.69-per-share unfavorable impact from acquired IPR&D and milestone expense incurred through the first nine months of 2026.
Management now expects approximately $67.8B in full-year revenue, a $200M increase from its prior outlook. At current exchange rates, AbbVie expects foreign currency to provide a roughly 0.5% benefit to full-year sales growth.
For the fourth quarter, management expects:
- Net revenue of approximately $18.4B, including a modest unfavorable foreign-exchange impact.
- Adjusted diluted EPS of $3.83 to $3.87.
- Full-year adjusted gross margin above 84% of sales.
- Full-year adjusted R&D expense of approximately $9.8B.
- Full-year adjusted SG&A expense of approximately $14.5B.
- Full-year adjusted operating margin of approximately 46.7% of sales, including a roughly 1.8% headwind from acquired IPR&D expense incurred through the third quarter.
The guidance excludes acquired IPR&D and milestone expenses that may occur after the third quarter because management said such items cannot be reliably forecast.
Balance Sheet, Cash Flow and Capital
AbbVie ended September with $10.8B in cash and generated approximately $14B in free cash flow during the first nine months of 2026. That total included nearly $2.7B of Skyrizi royalty payments.
The company completed the Apogee Therapeutics acquisition during the quarter, adding assets including zumilokibart, an IL-13 antibody in development for atopic dermatitis, and APG273, a potential long-acting IL-13 and TSLP combination program in asthma.
Management said AbbVie remains on track to reach a net leverage ratio of 2x over the next two to three years following the Apogee transaction. It also emphasized that free cash flow supports both the dividend and additional business development.
AbbVie raised its quarterly dividend 5.2% to $1.82 per share, beginning with the payment scheduled for February 2027.
What Investors Should Watch
1. Skyrizi and Rinvoq growth after new indications
The two immunology medicines are carrying a growing share of AbbVie’s revenue base. Investors should watch whether Skyrizi’s subcutaneous Crohn’s launch accelerates market share and whether Rinvoq’s potential vitiligo and alopecia launches build new markets as management expects.
2. Humira and Imbruvica erosion
Humira declined 31.2% and Imbruvica declined 26.1% in the quarter. AbbVie’s growth portfolio is more than offsetting these declines today, but the pace of erosion will affect the level of growth required from newer products.
3. Oncology pipeline conversion
Etentamig in multiple myeloma and Epkinly in frontline diffuse large B-cell lymphoma are among the company’s most important nearer-term pipeline opportunities. Management expects regulatory action on etentamig in 2027 and plans regulatory submissions for Epkinly next year. Commercial uptake and partnership economics will determine their financial contribution.
4. Aesthetics stabilization
The aesthetics business remains a drag on otherwise strong portfolio growth. A recovery in Juvederm demand, successful U.S. resolution for Boey, and sustained Botox Cosmetic growth would improve the segment’s outlook. Continued consumer softness would leave AbbVie more dependent on prescription medicines for growth.
5. Acquisition spending and leverage
The Apogee acquisition expands AbbVie’s immunology pipeline, but it also adds integration costs and acquired IPR&D expenses. Investors should monitor whether future business development remains focused on smaller bolt-on transactions, as management indicated, and whether leverage declines toward its 2x target.
AlgovestIQ Takeaway
AbbVie’s third quarter strengthened the case that its growth has moved beyond the Humira era. Skyrizi and Rinvoq remain the company’s most valuable commercial assets, while neuroscience is providing a second source of double-digit expansion through migraine, psychiatry, therapeutic Botox and Parkinson’s disease treatments.
The guidance increase is notable because it was driven by broad portfolio performance rather than a single product. Management raised revenue expectations for immunology, neuroscience and oncology, while keeping aesthetics guidance unchanged. That mix suggests the core pharmaceutical business is performing ahead of internal expectations even as consumer aesthetics remains uneven.
Still, the headline EPS growth overstates the underlying comparison because last year’s quarter carried unusually large acquired IPR&D and impairment charges. AbbVie’s adjusted operating margin remains high at 48.7%, but the sizable difference between GAAP and adjusted earnings should remain part of any assessment of recurring profitability.
The central question is whether AbbVie can sustain its current growth rate as Skyrizi and Rinvoq become larger products and competition intensifies. Evidence supporting that thesis would include continued share gains in IBD, successful launches in new dermatology indications, stabilization in aesthetics, and regulatory progress for etentamig, Epkinly and the expanded immunology pipeline. Slower uptake of new indications, faster erosion in legacy products, or continued weakness in aesthetics would make the company more reliant on its two leading immunology brands.
How did ABBV stock react?
ABBV closed at $294.89 on Oct 30, 2026, up 1.4% from $290.79 on Oct 29, 2026, the last close before the results were released.
| Session | Close | Change |
|---|---|---|
| Oct 29, 2026 (before release) | $290.79 | — |
| Oct 30, 2026 | $294.89 | +1.4% |
| Nov 2, 2026 | $288.84 | -0.7% |
Closing prices from AlgovestIQ market data. A move around a report also reflects the wider market.
More from this earnings season
- LLYEli Lilly Q3 2026 Earnings: Guidance Rises as Mounjaro and Zepbound Drive $24.4B QuarterOct 29, 2026
- MRKMerck Q3 2026 Earnings: Sales Growth Holds, but Purchase Timing and Higher Investment Pressure EPSOct 29, 2026
- GILDGilead Q3 2026 Earnings: Base Business Growth Accelerates as Biktarvy Pricing Risk Comes Into FocusOct 29, 2026
- BIIBBiogen Q3 2026 Earnings: Apellis Lifts Revenue Growth, but Acquisition Costs Depress EPSOct 28, 2026
- PFEPfizer Q3 2026 Earnings: Core Products Offset COVID Declines as Guidance RisesNov 3, 2026
Compare ABBV with
References
- Management commentary, analyst questions and outlook discussed on the call. Source: AbbVie Q3 FY2026 earnings call transcript, as of Oct 30, 2026.
- Reported results, segment figures and guidance from the company's results announcement. Source: AbbVie Form 8-K, Item 2.02 (SEC EDGAR), as of Oct 30, 2026.
- Reported revenue and EPS against analyst estimates, and the reported quarterly series. Source: AlgovestIQ reported-results data, as of Oct 30, 2026.
AI-generated analysis based on company-reported earnings data and earnings-call materials. Not investment advice.